Fispemifene
Phase 2Small molecule
Fispemifene is one of 126 small molecule programs targeting Hypogonadism. It is currently in Phase 2.
4
Indications
4
Total Trials
0
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Fispemifene
QQuatRx Pharmaceuticals Company
Phase 2
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypogonadism1 trial
Sexual Dysfunction1 trial
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
Unknown status·NNexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)·Phase 2·NCT02443090·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fispemifene. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- QQuatRx Pharmaceuticals Company